4,901 trials
Schistosomiasis
Primary: Proportion of Participants With of Any Serious Adverse Events (SAEs)/ Adverse Events of Special Interest (AESI) From the Time of the First Study Vaccination Through the…
Bioequivalence
Primary: Uncorrected and Baseline-corrected Sapropterin AUCt — 819.78; 805.79; 757.73; 755.15 hr*ng/mL
Prostate Cancer Metastatic
Primary: Safety Lead-in: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0 Participants
Opioid Use Disorder
Primary: Naltrexone Plasma Concentration Area Under the Curve (AUC₀-Day 98) — 11,556; 20,817; NA ng·hr/mL
Exocrine Pancreatic Insufficiency
Primary: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and AEs Leading to Study Discontinuation — 8; 8; 7; 7 Participants
Cocaine Use Disorder
Primary: Total Number of Treatment-Emergent Adverse Events (Safety and Tolerability) of Oral SXC-2023 Co-administered With Intravenous Cocaine — 99; 132 events
Heart Failure
Primary: To Investigate the Safety, Tolerability, Efficacy, and On-body Performance of a Novel Patch Infusor Device and Novel Furosemide Formulation Combination (SQIN-01) — 3; 1…
Thoracic Tumours
Primary: Toxicity Rate of Dose Limiting Toxicities (DLTs) Assessed by CTCAEv4 — 0; 0; 0; 0 Participants
Treatment-resistant Depression
Primary: Number of Participants Without Serious Adverse Events During Propofol Infusions — 16 Participants
Oncolytic Virotherapy
Primary: Safety Parameters — 4; 3; 3; 3 Participants
Drug-drug Interaction Study
Primary: Maximum Observed Plasma Concentration (Cmax) of Pitavastatin — 42.79; 33.54 ng/mL
Graft Vs Host Disease · Graft-versus-host-disease
Primary: Safety and Tolerability of Belimumab as Prophylaxis of Chronic GvHD in Subjects Following alloHCT as Measured by Number of Participants Who Experience Each Adverse Event…
Healthy
Primary: Area Under the Concentration-time Curve of BI 425809 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 4026.21; 4614.38…
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
HIV Infections · Pregnancy Related
Primary: Maximum Observed Plasma Concentration (Cmax) of Doraviraine During Pregnancy — 1340; 928; 1060; 252 ng/mL — p=0.400